Prime Medicine Shares Jump on FDA Clearance for Investigational New Drug Application
By Elias Schisgall
Shares of Prime Medicine jumped after the biotechnology company said the Food and Drug Administration cleared its investigational new drug application for PM647 to treat the genetic disease Alpha-1 Antitrypsin Deficiency.
Shares were up 13% to $3.47 in after-hours trading on Thursday after closing down 1.9% at $3.07. Through the close, the stock had fallen 12% this year.
The company said the FDA's clearance means it can initiate clinical studies in the U.S.
"FDA clearance of the PM647 IND is an important milestone for Prime Medicine, marking continued momentum across our liver franchise," Chief Executive Officer Allan Reine said. "PM647 has the potential to change how AATD is treated, offering a Prime Editing-based approach that moves beyond protein replacement and targets the root cause of disease."
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
September 24, 2026 17:23 ET (21:23 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States